UNITEDTable STATES SECURITIESof AND EXCHANGE COMMISSION Contents

~~WASHINGTON,~~UNITED ~~D.C.~~STATES SECURITIES ~~20549~~AND EXCHANGE COMMISSION

~~FORM~~WASHINGTON, ~~8-K~~D.C. 20549

~~CURRENT~~FORM ~~REPORT~~8-K ~~PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~

~~Date~~CURRENT ofREPORT PURSUANT ~~report~~TO SECTION 13 OR 15(~~Date~~d) ofOF THE ~~earliest~~SECURITIES ~~event~~EXCHANGE ~~reported):~~ACT ~~May 28,~~OF ~~2010~~1934

~~JAVELIN~~Date ~~PHARMACEUTICALS~~of report (Date of earliest event reported): July 1, ~~INC.~~2010

~~(Exact~~JAVELIN ~~name~~PHARMACEUTICALS, ~~of registrant as specified in its charter)~~INC.

Delaware		001-32949		88-0471759
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

(Exact name of registrant as specified in its charter)

~~125~~Delaware ~~CambridgePark~~(State ~~Drive,~~or ~~Cambridge,~~other ~~Massachusetts~~jurisdiction ~~02140 (Address~~ of ~~Principal~~incorporation ~~Executive~~or ~~Offices~~organization) 001-32949 (~~Zip~~Commission ~~Code~~File Number) 88-0471759 (I.R.S. Employer Identification No.)

125 CambridgePark Drive, Cambridge, Massachusetts 02140 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code: (617) 349-4500

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~o Soliciting~~TABLE ~~material~~OF ~~pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)~~ CONTENTS

~~o Pre-commencement~~Item ~~communications~~2.01 ~~pursuant~~Completion of Acquisition or Disposition of Assets Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule ~~14d-2(b)~~ ~~under~~or ~~the~~Standard; ~~Exchange~~Transfer ~~Act~~of ~~(17 CFR~~Listing ~~240~~Item 3.~~14d~~03 Material Modification to Rights of Security Holders Item 5.01 Change in Control of Registrant Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers Item 5.03 Amendments to Articles of Incorporation of Bylaws; Change of Fiscal Year Item 8.01 Other Events Item 9.01 Financial Statements and Exhibits SIGNATURE EXHIBIT LIST EX-3.1 EX-3.2~~(b))~~

o Pre-commencementTable communicationsof pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Contents

Item 32.01 ~~Notice~~Completion of ~~Delisting~~Acquisition or ~~Failure~~Disposition ~~to Satisfy a Continued Listing Rule or Standard; Transfer~~ of ~~Listing~~Assets.

On ~~May~~July 282, 2010, pursuant to the previously disclosed Agreement and Plan of Merger, dated as of April 17, 2010 (the “Merger Agreement”), by and among Hospira, Inc., a Delaware corporation (“Parent”), Discus Acquisition Corporation, a Delaware corporation and wholly owned subsidiary of Parent (“Purchaser”), and Javelin Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Parent ~~received~~completed ~~notice~~its ~~from~~acquisition of the Company. The transaction was consummated through a tender ~~staff~~offer by Purchaser pursuant to which Purchaser offered to purchase each outstanding share of ~~the~~common stock, ~~NYSE~~par ~~Amex~~value ~~LLC~~$.001 per share, of the Company (the “~~Exchange~~Shares” or “Common Stock”), ~~that~~at a purchase price of $2.20 per Share, ~~based~~net onto the ~~Exchange’s~~seller ~~review~~in ofcash, ~~publicly~~without interest thereon and less any required ~~available~~withholding ~~information~~taxes (the “Offer”), upon the ~~Company~~terms isand ~~not~~subject to the conditions set forth in ~~compliance~~the Offer ~~with~~to ~~Section 1003(a)(iv)~~Purchase ofdated ~~Part~~April 1021, of2010 and in the related Letter of Transmittal, each ~~NYSE~~as ~~Amex~~filed ~~LLC~~with ~~Company~~the ~~Guide~~Securities and Exchange Commission (the “~~Company Guide~~SEC”). ~~Specifically~~on April 21, ~~after~~2010 ~~reviewing~~as ~~the~~exhibits ~~Company~~to Parent’s ~~Quarterly~~ ~~Report~~and onPurchaser’s ~~Form~~Tender ~~10-Q~~Offer ~~for~~Statement ~~the~~on ~~quarter ended March~~Schedule 31TO, ~~2010~~as amended, followed by the ~~Exchange~~merger ~~staff~~of ~~indicated~~the ~~that~~Company with and into Purchaser (the “Merger”), with the Company ~~has~~surviving ~~sustained~~as ~~losses~~a ~~which~~wholly ~~are~~owned subsidiary soof ~~substantial~~Parent. inAt ~~relation~~the toeffective ~~its~~time ~~overall~~of ~~operation or~~the ~~its~~Merger ~~existing~~(the ~~financial~~“Effective ~~resources~~Time”), oreach ~~its~~Share ~~financial~~not validly ~~condition~~tendered ~~has~~in ~~become~~the soOffer ~~impaired~~(other ~~that~~than ~~it appears~~Shares ~~questionable,~~held in the ~~opinion~~treasury of the ~~Exchange~~Company and Shares held by (i) Parent, asPurchaser toor ~~whether~~any other wholly owned subsidiary of Parent or the Company ~~will~~or be(ii) stockholders ~~able~~who properly demand and perfect appraisal rights under Delaware law) was converted into the right to receive an amount in cash equal to $2.20, net to the seller in cash, without ~~continue~~interest ~~operations~~thereon and~~/or~~ ~~meet~~less ~~its~~any ~~obligations~~required aswithholding ~~they~~taxes ~~mature~~(the “Merger Consideration”).

AsThe aforegoing ~~result,~~description of the ~~Company~~Merger ~~has~~Agreement ~~become~~(including ~~subject to~~ the ~~procedures~~description ~~and requirements~~ of ~~Section 1009~~the ofconsideration ~~the~~paid ~~Company~~in ~~Guide.~~connection Towith ~~maintain its listing,~~ the ~~Company~~Merger) ~~must~~does ~~submit~~not apurport ~~plan~~ to ~~the~~be ~~Exchange~~complete ~~by June 11,~~and ~~2010,~~is ~~advising~~qualified in ~~the~~its ~~Exchange~~entirety ~~how~~by itreference ~~intends~~ to ~~regain~~the ~~compliance~~Merger ~~with~~Agreement, ~~Section 1003(~~a~~)(iv)~~ copy of ~~the~~which ~~Company~~was ~~Guide~~filed byas ~~August~~Exhibit ~~26, 2010~~2.1 ~~The Company intends~~ to the ~~submit~~Form a8-K ~~plan~~filed toby ~~regain~~the ~~compliance to~~Company with the ~~Exchange~~SEC byon ~~June~~April 1119, 2010.

~~Following~~Item 3.01 ~~submission~~Notice of ~~the~~Delisting ~~plan,~~or ~~the~~Failure ~~Corporate Compliance Department of the Exchange will evaluate the plan~~ to ~~determine~~Satisfy ~~whether the Company has made~~ a ~~reasonable~~Continued ~~demonstration~~Listing inRule the plan of an ability to regain compliance with the continued listing standards by August 26, 2010. If the plan is accepted, the Company may be able to continue its listing while implementing the plan, during which time it will be subject to periodic review to determine whether it is making progress consistent with the plan. If the plan is not accepted, if the plan is accepted but the Company fails to make progress consistent with the plan or ifStandard; ~~the~~Transfer ~~Company~~of ~~has failed to regain compliance by August 26, 2010, then the Company will be subject to delisting proceedings~~Listing. ~~Under the Company~~ ~~Guide, the Company may appeal any determination by the Exchange to initiate delisting proceedings.~~

OnThe ~~June 4,~~disclosure ~~2010,~~set ~~the~~forth ~~Company~~under ~~issued~~Item 2.01 ~~a press release announcing its receipt of the notice of its failure to satisfy the continued listing standard referenced~~ above. ~~The full text of this press release~~ is ~~attached~~incorporated ~~hereto~~herein asby ~~Exhibit 99~~reference.1.

~~Item~~ As a result of the Merger, the Company no longer fulfills the numerical listing requirements of the NYSE Amex LLC (“Amex”). Accordingly, the Company has requested that the Common Stock be withdrawn from listing on Amex as of the opening of trading on July 96, 2010.~~01.~~ ~~Financial~~Amex ~~Statements~~has advised the Company that it will file with the Securities and ~~Exhibits~~Exchange Commission (the “SEC”) a Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on Form 25 to delist and deregister the Common Stock. Upon the filing of the Form 25 by Amex, the Shares will no longer be listed on Amex.

~~(d)~~Item ~~Exhibits~~3.03 Material Modification to Rights of Security Holders.

~~Exhibit~~ The ~~99.1~~disclosure ~~Press~~set ~~Release~~forth ~~issued~~under byItem 2.01 ~~Javelin~~above ~~Pharmaceuticals,~~is ~~Inc.~~incorporated onherein ~~June~~by ~~4, 2010~~reference.

~~SIGNATURE~~ In connection with the consummation of the Merger, each Share issued and outstanding immediately prior to the Effective Time (other than Shares held in the treasury of the Company and Shares held by (i) Parent, Purchaser or any other wholly owned subsidiary of Parent or the Company or (ii) stockholders who properly demand and perfect appraisal rights under Delaware law) has been converted into the right to receive the Merger Consideration. At the Effective Time, Company stockholders immediately prior to the Effective Time ceased to have any rights as stockholders of the Company (other than their right to receive the Merger Consideration or seek the payment of the fair value of their Shares under Delaware law) and accordingly no longer have any interest in the Company’s future earnings or growth.

~~Pursuant~~Item 5.01 toChange ~~the~~in ~~requirements~~Control of ~~the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized~~Registrant.

	Javelin Pharmaceuticals, Inc.
Date: June 4, 2010	By:	/s/ Martin J. Driscoll
		Name:	Martin J. Driscoll
		Title:	Chief Executive Officer

The disclosure set forth under Item 2.01 above and Item 5.02 below is incorporated herein by reference. As a result of the Merger, a change in control of the Company occurred and the Company has become a wholly owned subsidiary of Parent.

EXHIBITTable LIST of Contents

~~Exhibit 99~~Item 5.102 ~~Press~~Departure ~~Release~~of ~~issued~~Directors byor ~~Javelin~~Principal ~~Pharmaceuticals,~~Officers; ~~Inc.~~Election onof ~~June~~Directors; 4,Appointment ~~2010~~of Principal Officers.

As of the Effective Time, in connection with the Merger, the Company’s existing directors and principal officers voluntarily resigned. Pursuant to the Merger Agreement, upon consummation of the Merger, the directors and officers of Purchaser immediately prior to the consummation of the Merger became the directors and officers, respectively, of the Company, in each case until their successors are duly elected or appointed and qualified.

Following the Effective Time, Richard J. Hoffman became the sole director of the Company and Richard J. Hoffman and Brian J. Smith became the Company’s President and Treasurer and Vice President and Secretary, respectively.

Item 5.03 Amendments to Articles of Incorporation of Bylaws; Change of Fiscal Year.

Pursuant to the Merger Agreement, upon consummation of the Merger, the certificate of incorporation of the Company was amended and restated in its entirety so as to contain the provisions, and only the provisions, contained in the certificate of incorporation of Purchaser in effect immediately prior to the consummation of the Merger (except that Article I of the amended certificate of incorporation reads as follows: “The name of the corporation is Javelin Pharmaceuticals, Inc.”). Also, upon consummation of the Merger, the amended and restated bylaws of Purchaser in effect immediately prior to the consummation of the Merger became the amended and restated bylaws of the Company, except that such bylaws were amended to reflect that the name of the Company is Javelin Pharmaceuticals, Inc.

The amended and restated certificate of incorporation and bylaws of the Company are attached hereto as Exhibits 3.1 and 3.2, respectively, and are incorporated herein by reference.

Item 8.01 Other Events.

On July 1, 2010, the Company issued a press release announcing the expiration of the offering period and the successful completion of the Offer for the Shares, a copy of which is attached as Exhibit 99.1 hereto and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.


Exhibit 3.1		Amended and Restated Certificate of Incorporation of Javelin Pharmaceuticals, Inc.

Exhibit 3.2		Amended and Restated Bylaws of Javelin Pharmaceuticals, Inc.

Exhibit 99.1		Press Release issued by Javelin Pharmaceuticals, Inc. on July 1, 2010 (incorporated by reference to Exhibit (a)(25) to Javelin Pharmaceuticals, Inc.’s Amendment No. 8 to its Solicitation / Recommendation Statement on Schedule 14D-9, filed with the Securities and Exchange Commission on July 1, 2010).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	Javelin Pharmaceuticals, Inc.
Date: July 2, 2010	By:	/s/ Martin J. Driscoll
		Name:	Martin J. Driscoll
		Title:	President and Chief Executive Officer

EXHIBIT LIST


Exhibit 3.1		Amended and Restated Certificate of Incorporation of Javelin Pharmaceuticals, Inc.

Exhibit 3.2		Amended and Restated Bylaws of Javelin Pharmaceuticals, Inc.

Exhibit 99.1		Press Release issued by Javelin Pharmaceuticals, Inc. on July 1, 2010 (incorporated by reference to Exhibit (a)(25) to Javelin Pharmaceuticals, Inc.’s Amendment No. 8 to its Solicitation / Recommendation Statement on Schedule 14D-9, filed with the Securities and Exchange Commission on July 1, 2010).

UNITEDTable STATES SECURITIESof AND EXCHANGE COMMISSION Contents

o Pre-commencementTable communicationsof pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Contents

EXHIBITTable LIST of Contents

Table of Contents

Table of Contents

Filing Compare · JAVELIN PHARMACEUTICALS, INC